Mr. Tony O'Brien:

The Deputy could interpret it that way, but clearly there are market size differences. Some of the bigger markets have a bigger range of players and are more attractive to some of the generic off-brand manufacturers than a small market such as Ireland. So it is difficult to compare the ability of our negotiators simply based on the cost outcome. When one is negotiating as opposed to legislating, it is a different thing. As we move towards legislation for reference pricing, that will be a game changer in terms of the price of medications in Ireland.